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Predictive factors of mortality among type 2 diabetic patients: do not
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The association between diabetes and cardiovascular diseases is well estab-
lished, as still the main cause of death among these patients. We followed a
cohort of 703 high risk type 2 diabetic patients during a median follow up of
5,8 years and thought to determine predictive factors associated with mortality
and cardiovascular mortality.
Methods: Survival analysis was made. For univariate analysis, we used
Kaplan Meyer methods. Covariables with p-value < 0.15 at log-rank test were
introduced in COX multivariate analysis. Significant variables were selec-
tioned for final model selection through STEPWISE, BACKWARD, FOR-
WARD methods.
Results: Among these patients, 58% were male, mean age of 62,06 years,
with a mean length of diabetes of 13,80 years and a HbA1c of 8,35%. 29%
had positive microalbuminuria or proteinuria, 14% had a creatinin clearance
inferior to 60 ml/min. 12% had obliterating arteriopathy of the lower limbs
definied by pulse abolition. Mean LDL was 1,10 g/l, 54% of these patients
were under statin treatment. 60% were classified as having hypertension, and
43% were currents somokers. During follow up, 67 patients died (9,5%) with
mainly cardiovascular death (57 patients). In multivariate analysis, obliterating
arteriopathy of the lower limbs, insulin treatment, antiagregant treatment,
triglyceride level above 1,5 g/l were associated with global mortality.
Regarding predictive factors associated with cardiovascular mortality, we
found that obliterating arteriopathy of the lower limbs, creatinin clearance under
60 ml/min and high systolic blood pressure were associated. Obliterating arte-
riopathy of the lower limbs was the strongest predictor of mortality (RR=2,68;
IC95%:1,58-4,52) and of cardiovascular mortality (RR=2,79; IC95%:1,68-
4,64).
Conclusion: Presence of obliterating arteriopathy of the lower limbs diag-
nosed by clinical examination was the strongest factor associated with global
and cardiovascular mortality in high risk type 2 diabetic patients.
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The aims of this study were in obese patients to evaluate the role of predi-
abetes in LVH before bariatric surgery and in the changes of LV mass after
surgery.
Research methods: Echocardiography was performed in 107 obese
patients. After exclusion of 34 patients due to diabetes or obstructive sleep
apnea and 4 patients with a poor quality imaging, 69 echocardiographies could
be analysed: 55 women and 14 men, age 35.6±11.1 years, mean BMI
43.3±4.8 kg/m², mean blood pressure 121/71 mmHg. An oral glucose tolerance
test (OGTT) was performed in these patients.
Results: Prediabetes was diagnosed in 32% of the patients, and 50% had
insulin resistance as defined by HOMA-IR >3. Nine patients (13%) had
LVH (LV mass (LVM) indexed on height: LVM/h >1.21 g/m² in women and
1.63 g/m² in men). LVM correlated with fat-free mass (p<0.001), waist/hip
ratio (p<0.001), fasting plasma glucose and 2-h OGTT glucose (p=0.015 and
0.045). In multivariate regression analysis LVM/h was still associated with
2h OGTT glucose. LVM/h was significantly higher in patients with pre-
diabetes and/or insulin resistance (p=0.013). Echocardiographic parameters
were again measured in 26 patients 6 to 50 months (mean 17.6) after bari-
atric surgery (modulable banding gastroplasty 52%, sleeve-gastrectomy 33%
and by-pass 15%), which induced a mean weight loss of 22.8%. Changes in
LVM correlated weakly with body weight changes (p=0.04), glucose tole-
rance was normalized in 4 of 8 patients with prediabetes. LVH persisted in
4 out of 8 patients. Half patients who increased their LVM were prediabetic
preoperatively whereas all the patients who reduced their LVM (– 14% in
means) were normoglycemic preoperatively (p=0.03). LVM changes were
associated significantly with body weight changes and glycemic status at
inclusion.
Conclusion: prediabetes is a determinant factor of LVM and its post-sur-
gical change. Weight loss after surgery is associated with LVM decrease only
in patients with a normal glucose tolerance.
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Serum adiponectin and long term mortality in coronary heart disease
patients and control patients
Sébastien Hascoët (1), Meyer Elbaz (1), Vanina Bongard (2), Frederic
Bouisset (1), Bertrand Perret (3), Céline Verdier (3), Michel Galinier (1),
Didier Carrié (1), Jean Ferrière (2), Jean-Bernard Ruidavets (2)
(1) CHU Rangueil, cardiology, Toulouse, France – (2) CHU, epidemio-
logy, U 10 27, Inserm, Toulouse, France – (3) CHU Purpan, Biochemis-
try, U 10 48, Inserm, Toulouse, France
Objective: we investigated in 715 men aged 45-74 with stable coronary
artery disease (CAD) and 782 controls whether serum adiponectin was asso-
ciated with long-term total and cardiovascular diseases (CVD) mortality,
considering varying degrees of CAD severity.
Methods and results: adiponectin was lower in patients (5.6±0.2 µg/mL)
than in controls (7.1±0.2 µg/mL), (p<0.001) but became similar after mul-
tivariate adjustment (6.1±0.3 µg/mL) and (6.5±0.3 µg/mL) respectively
(p=0.17). During a median follow-up of 8.1 years, survival rates among
CAD patients in increasing quartiles of serum adiponectin values were
87.5%, 85.6%, 76.4% and 67.6%, respectively (p<0.001 by log-rank test).
Survival rates in controls with adiponectin <9.1 µg/mL and ≥9.1 µg/mL
(third quartile) were 95.3% and 91.0% respectively (p=0.035 by log-rank
test). Adiponectin concentration above the highest quartile was associated
with an increased risk of all-cause and cardiovascular mortality in CAD
patients (p=0.001 and p=0.001 respectively) and in controls (p=0.03 and
p=0.01 respectively). An increase of 1 µg/mL of adiponectin was associ-
ated with an increased risk of total mortality of 8.0% (HR= 1.08 [95% CI
1.05-1.11], p<0.001) in the whole population, combining both CAD
patients and controls. The associations between high adiponectin and total
or cardiovascular mortality remained significant after multivariate adjust-
ment.
Conclusion: high serum adiponectin is a powerful predictor of mortality
particularly from CVD. This prognostic value remains significant whatever
the severity of the CAD and is not different among people with and without
CAD.
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